Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Thursday. The firm set a “hold” rating on the medical research company’s stock.

CTSO has been the topic of a number of other research reports. D. Boral Capital reissued a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a research note on Monday, January 13th. HC Wainwright reissued a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a research note on Monday, November 11th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Price Performance

Shares of CTSO stock opened at $1.01 on Thursday. The stock’s fifty day simple moving average is $0.96 and its 200 day simple moving average is $1.04. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The firm has a market cap of $55.23 million, a price-to-earnings ratio of -2.81 and a beta of 0.61. Cytosorbents has a one year low of $0.70 and a one year high of $1.59.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings results on Thursday, November 7th. The medical research company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03). The company had revenue of $9.39 million during the quarter, compared to analyst estimates of $10.14 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. During the same period in the prior year, the firm earned ($0.21) EPS. On average, analysts expect that Cytosorbents will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cytosorbents

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its holdings in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the last quarter. Sargent Investment Group LLC increased its holdings in Cytosorbents by 13.4% in the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after purchasing an additional 192,747 shares during the last quarter. Atomi Financial Group Inc. bought a new stake in Cytosorbents in the third quarter valued at about $51,000. Finally, Skylands Capital LLC increased its holdings in Cytosorbents by 1.0% in the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after purchasing an additional 26,195 shares during the last quarter. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.